79. 家族性高コレステロール血症(ホモ接合体) Homozygous familial hypercholesterolemia Clinical trials / Disease details
臨床試験数 : 145 / 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17
Showing 1 to 10 of 18 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2017-003170-13-AT (EUCTR) | 23/07/2019 | 11/02/2019 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;Sou ... | ||
2 | EUCTR2017-003170-13-IT (EUCTR) | 18/02/2019 | 22/01/2021 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia - na An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 20.0;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000004850 MedDRA version: 20.0;System Organ Class: 100000004850;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 20.0;Level: LLT;Classification code 1005708 ... | Trade Name: na Product Name: Evinacumab (REGN1500) Product Code: [REGN1500] INN or Proposed INN: Evinacumab Other descriptive name: Evinacumab Trade Name: Praluent Product Name: Praluent Product Code: [na] INN or Proposed INN: alirocumab Trade Name: na Product Name: Evinacumab(REGN1500) Product Code: [REGN1500] INN or Proposed INN: Evinacu ... | REGENERON PHARMACEUTICALS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 3 | United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Norway;Germany;Netherlands;Japan United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Austr ... | ||
3 | EUCTR2017-003170-13-GR (EUCTR) | 01/02/2019 | 14/01/2019 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Czechia;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Austr ... | ||
4 | EUCTR2017-003170-13-CZ (EUCTR) | 17/12/2018 | 11/10/2018 | Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hyperc ... | An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with hom ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 121 | Phase 3 | United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands;Japan United States;Greece;Ukraine;Austria;United Kingdom;Italy;France;Czech Republic;Canada;Australia;Sou ... | ||
5 | EUCTR2017-002297-39-DK (EUCTR) | 03/09/2018 | 04/06/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Homozygous Familial Hype ... | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents wi ... | Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603;Term: Hypercholesterolaemia;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] Homozygous Familial Hypercholesterolemia MedDRA version: 20.0;Level: PT;Classification code 10020603 ... | Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Other descriptive name: ALIROCUMAB Trade Name: Praluent Product Name: Alirocumab Product Code: SAR236553 INN or Proposed INN: Alirocumab Ot ... | Sanofi-Aventis Recherche & Développement | NULL | Not Recruiting | Female: yes Male: yes | 50 | Phase 3 | United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Argentina;Brazil;Denmark;Bulgaria;Netherlands;Norway United States;Taiwan;Slovenia;Spain;Turkey;Austria;Russian Federation;Italy;France;Mexico;Canada;Arg ... | ||
6 | EUCTR2017-001388-19-DE (EUCTR) | 18/06/2018 | 23/01/2018 | A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high) cholesterol level A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high ... | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and sa ... | Homozygous familial hypercholesterolemia MedDRA version: 20.1;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861 ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 20.1;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 57 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Afric ... | ||
7 | EUCTR2017-001388-19-IT (EUCTR) | 11/05/2018 | 11/02/2021 | A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high) cholesterol level A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high ... | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia - - A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and sa ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Trade Name: Praluent Product Name: Alirocumab Product Code: [REGN7272] INN or Proposed INN: Alirocumab Other descriptive name: Alirocumab Product Name: Evinacumab Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: Evinacumab Trade Name: Praluent Product Name: Alirocumab Product Code: [REGN7272] INN or Proposed INN: Alirocumab O ... | REGENERON PHARMACEUTICALS, INC. | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 3 | United States;Czechia;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands United States;Czechia;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;Sou ... | ||
8 | EUCTR2017-001388-19-GR (EUCTR) | 02/05/2018 | 02/04/2018 | A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high) cholesterol level A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high ... | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and sa ... | Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 21.0;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 65 | Phase 3 | United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Africa;Netherlands;Germany;Japan United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Afric ... | ||
9 | EUCTR2017-001388-19-AT (EUCTR) | 23/03/2018 | 30/01/2018 | A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high) cholesterol level A study to evaluate the safety and efficacy of evinacumab in patients with Hereditary abnormal (high ... | A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and sa ... | Homozygous familial hypercholesterolemia MedDRA version: 20.1;Level: LLT;Classification code 10020604;Term: Hypercholesterolemia;System Organ Class: 100000004861;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] Homozygous familial hypercholesterolemia MedDRA version: 20.1;Level: LLT;Classification code 1002060 ... | Product Name: Evinacumab (REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descriptive name: EVINACUMAB Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB Product Name: Evinacumab(REGN1500) Product Code: REGN1500 INN or Proposed INN: Evinacumab Other descrip ... | Regeneron Pharmaceuticals Inc. | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 3 | United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Africa;Germany;Netherlands United States;Greece;Ukraine;Turkey;Austria;Italy;France;Czech Republic;Canada;Australia;South Afric ... | ||
10 | EUCTR2017-000351-95-DE (EUCTR) | 13/12/2017 | 17/08/2017 | A study to the safety and efficacy of alirocumab in patients with Hereditary abnormal (high) cholesterol level A study to the safety and efficacy of alirocumab in patients with Hereditary abnormal (high) cholest ... | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - ODYSSEY HoFH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SA ... | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA MedDRA version: 20.0;Level: LLT;Classification code 10057080;Term: Homozygous familial hypercholesterolemia;System Organ Class: 100000012386;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA MedDRA version: 20.0;Level: LLT;Classification code 1005708 ... | Trade Name: Praluent INN or Proposed INN: ALIROCUMAB Other descriptive name: ALIROCUMAB | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 54 | Phase 3 | France;United States;Czech Republic;Greece;Canada;Ukraine;Turkey;Austria;South Africa;Germany;Italy |